MY139546A - 5ht4 partial agonist pharmaceutical compositions - Google Patents

5ht4 partial agonist pharmaceutical compositions

Info

Publication number
MY139546A
MY139546A MYPI20024825A MYPI20024825A MY139546A MY 139546 A MY139546 A MY 139546A MY PI20024825 A MYPI20024825 A MY PI20024825A MY PI20024825 A MYPI20024825 A MY PI20024825A MY 139546 A MY139546 A MY 139546A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical compositions
partial agonist
weight
amount
agonist pharmaceutical
Prior art date
Application number
MYPI20024825A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY139546A publication Critical patent/MY139546A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20024825A 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions MY139546A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
MY139546A true MY139546A (en) 2009-10-30

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20024825A MY139546A (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Country Status (31)

Country Link
US (2) US20050106236A1 (https=)
EP (2) EP1321142A1 (https=)
JP (1) JP4718776B2 (https=)
KR (1) KR100980144B1 (https=)
CN (1) CN100464749C (https=)
AR (1) AR037937A1 (https=)
AT (1) ATE320807T1 (https=)
AU (1) AU2002361198B2 (https=)
BR (1) BR0215148A (https=)
CA (1) CA2470668C (https=)
CO (1) CO5640102A2 (https=)
CY (1) CY1105559T1 (https=)
DE (1) DE60210139T2 (https=)
DK (1) DK1458377T3 (https=)
EC (1) ECSP105163A (https=)
EG (1) EG24194A (https=)
ES (1) ES2258171T3 (https=)
HU (1) HU226589B1 (https=)
IL (2) IL162451A0 (https=)
MX (1) MXPA04006157A (https=)
MY (1) MY139546A (https=)
NO (1) NO20042779L (https=)
NZ (1) NZ533585A (https=)
PE (1) PE20030872A1 (https=)
PL (1) PL369509A1 (https=)
PT (1) PT1458377E (https=)
RU (1) RU2322978C2 (https=)
SI (1) SI1458377T1 (https=)
TW (1) TWI260221B (https=)
WO (1) WO2003053432A1 (https=)
ZA (1) ZA200404467B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050119328A1 (en) * 2003-03-25 2005-06-02 Hetero Drugs Limited Novel crysalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
KR20060111675A (ko) * 2003-12-16 2006-10-27 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 염기 및 그것의 염의 다형태
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Also Published As

Publication number Publication date
BR0215148A (pt) 2004-10-19
US20090104263A1 (en) 2009-04-23
DK1458377T3 (da) 2006-06-12
IL162451A (en) 2009-02-11
EP1321142A1 (en) 2003-06-25
WO2003053432A1 (en) 2003-07-03
AU2002361198A1 (en) 2003-07-09
JP2005516946A (ja) 2005-06-09
CA2470668A1 (en) 2003-07-03
DE60210139T2 (de) 2006-08-17
IL162451A0 (en) 2005-11-20
KR20040066922A (ko) 2004-07-27
PE20030872A1 (es) 2003-11-24
CO5640102A2 (es) 2006-05-31
HU226589B1 (en) 2009-04-28
ATE320807T1 (de) 2006-04-15
NZ533585A (en) 2006-04-28
RU2322978C2 (ru) 2008-04-27
ZA200404467B (en) 2006-05-31
RU2004122631A (ru) 2005-08-10
CN1606438A (zh) 2005-04-13
HUP0402492A3 (en) 2008-04-28
TWI260221B (en) 2006-08-21
AR037937A1 (es) 2004-12-22
SI1458377T1 (sl) 2006-08-31
TW200410684A (en) 2004-07-01
JP4718776B2 (ja) 2011-07-06
ES2258171T3 (es) 2006-08-16
EP1458377A1 (en) 2004-09-22
CN100464749C (zh) 2009-03-04
CY1105559T1 (el) 2010-07-28
EG24194A (en) 2008-10-14
US20050106236A1 (en) 2005-05-19
PL369509A1 (en) 2005-04-18
NO20042779L (no) 2004-09-17
AU2002361198B2 (en) 2006-06-08
CA2470668C (en) 2011-07-05
MXPA04006157A (es) 2004-10-27
HUP0402492A2 (hu) 2005-07-28
EP1458377B1 (en) 2006-03-22
ECSP105163A (es) 2010-07-30
PT1458377E (pt) 2006-07-31
KR100980144B1 (ko) 2010-09-03
DE60210139D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
MY139546A (en) 5ht4 partial agonist pharmaceutical compositions
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
AP1739A (en) Azaindoles
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
ZA200104188B (en) Use of alpha-keto enamine derivaties as ingredients.
TW200633730A (en) Oral disintegrating dosage forms
JO2339B1 (en) Benzamidazole compounds
IL150986A0 (en) 1,2,3,4,- tetrahydroisoquinoline derivatives
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
IL179718A0 (en) Pharmaceutical composition containing irbesartan
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
BG105436A (en) Pharmaceutical compositions comprising entacapone or nitecapone as well as a cross-linked cellulpse derivative
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
SG162605A1 (en) Pharmaceutical compositions
PT1635792E (pt) Composições farmacêuticas estáveis de derivados do ácido 2-aza-biciclo[3.3.0]octano-3-carboxílico
MY129314A (en) Pharmaceutical composition comprising sumatriptan
BR0315016A (pt) Composição fumìgena
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
WO2002055062A3 (en) Pharmaceutical tablet comprising paroxetine mesylate
TW200505504A (en) Saquinavir mesylate oral dosage form